While CSL’s blood plasma products may avoid the levy, the new tariffs put pressure on the Albanese government to do a deal to protect other drugmakers.
Australia will not be strong-armed to pay more for medicines because of tariffs and higher prices in the US, Health Minister ...
Is AstraZeneca on track to meet its $80 billion revenue target? In 2024, AstraZeneca’s CEO Pascal Soriot set a new goal: for the company to pull in $80 billion in annual sales by 2030. (Endpoints News ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results